Key result
Venous thromboembolism in patients with cancer poses significant treatment challenges due to a multitude of risk factors and greater risks of recurrence and mortality.
VTE in cancer patients presents unique challenges due to multiple risk factors and higher rates of recurrence and mortality, requiring careful management.
Answers are grounded in this paper and cite their sources.
Supports vigilant VTE care in cancer; leaves open optimal regimens and durations.
The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain about the close relationship between VTE and malignant disease. The risk of VTE among patients with cancer continues to increase and is clearly linked to patient-, disease- and treatment-specific factors. In general, VTE among patients with cancer is treated in a similar fashion to that in other patient populations. However, the greater risk of VTE in patients with cancer, the multitude of risk factors, and the greater risk of VTE recurrence and mortality among patients with cancer pose important challenges for surgeons, oncologists, and other providers.
No takes yet. Share an insight, caveat, or question.
Lyman et al. (2013) conducted a review in Venous thromboembolism in cancer. Venous thromboembolism treatment and prevention was evaluated. Venous thromboembolism in patients with cancer poses significant treatment challenges due to a multitude of risk factors and greater risks of recurrence and mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: